Share:

Latent Tuberculosis Infection LTBI Testing Market Size, Share & Trends Analysis Report By Product (Tuberculin Skin Test (TST), Interferon Gamma Released Assay (IGRA), and Latent Tuberculosis Infection (LTBI)), By Applications (Hospitals and Clinics, Diagnostic Laboratories, Others), By End Use, By Region, and Segment Forecasts - 2035

Last Updated: 09 September 2026
Base Year: 2025
Historical Data: 2021-2024
No of Pages: 125
  • The Latent Tuberculosis Infection LTBI Testing Market is projected to reach USD 2683.18 Million by 2035, expanding at a steady pace during the forecast period. Market growth is supported by rising demand, technological advancements, and increasing adoption across major end-use industries worldwide.

  • What is the expected CAGR of the Latent Tuberculosis Infection LTBI Testing Market during 2026-2035?

    The Latent Tuberculosis Infection LTBI Testing Market is expected to grow at a CAGR of 9.42% during the forecast period from 2026 to 2035.

  • Which companies are leading the Latent Tuberculosis Infection LTBI Testing Market?

    Key players in the Latent Tuberculosis Infection LTBI Testing Market market include Par Sterile (U.S.), Thermo Fisher Scientific (U.S.), Oxford Immunotec (U.K.), Bio-Rad Laboratories(U.S.), Qiagen (Germany), Sanofi (France)

  • How large was the Latent Tuberculosis Infection LTBI Testing Market in 2025?

    The Latent Tuberculosis Infection LTBI Testing Market was valued at USD 1871.82 Million in 2025, reflecting strong demand and continued adoption across major industries.

What is included in this Sample?

man icon
Mail icon
Captcha refresh